scholarly journals ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study

2019 ◽  
Vol 145 (3) ◽  
pp. 765-774 ◽  
Author(s):  
Sanna Iivanainen ◽  
Tuomo Alanko ◽  
Katriina Peltola ◽  
Teemu Konkola ◽  
Jussi Ekström ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Cancer Patients ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors

Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?

Immunotherapy ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 409-418
Author(s):  
Stijn J De Keukeleire ◽  
Tijl Vermassen ◽  
Zahra M Nezhad ◽  
Tessa Kerre ◽  
Vibeke Kruse ◽  
...  
Keyword(s):  
Viral Hepatitis ◽  
Cancer Patients ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Chronic Viral Hepatitis ◽  
Viral Clearance ◽  
Viral Reactivation ◽  
Immune Checkpoints

More patients with chronic hepatitis B and C infection are being exposed to immune checkpoint inhibitors (ICIs), but the safety and efficacy of ICIs in patients with chronic viral hepatitis are still poorly described. To explore this interaction, we identified eight studies of cancer patients with viral hepatitis treated with one or more ICIs, formally assessed tumor responses and safety by grading liver dysfunction. ICIs appear to be relatively safe in HBV/HCV-infected patients, and hepatitis related to viral reactivation is rare. In some patients, viral load regressed during ICI treatment, so immune checkpoints may play a role in viral clearance. HBV/HCV do not appear to be a contraindication to ICIs, although careful clinical and biochemical follow-up is recommended and, whenever necessary, antiviral therapy commenced.

Early changes in lymphocyte/monocyte ratio on-treatment as a prognostic marker to predict overall survival in patients with advanced cancer treated with immune checkpoint inhibitors

2021 ◽  
Author(s):  
Sandip H. Patel ◽  
Songzhu Zhao ◽  
Mingjia Li ◽  
Lai Wei ◽  
Marium Husain ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Predictive Biomarker ◽  
Advanced Cancer Patients ◽  
High Baseline

Abstract Background A low absolute lymphocyte/monocyte ratio (LMR) in the peripheral blood is associated with poor prognosis in various cancers; however, its role as a predictive biomarker has not been well defined in the era of treatment with immune checkpoint inhibitors (ICI). Methods We queried a database of advanced cancer patients treated with at least one dose of ICI from 2011 to 2017 to study the association of LMR with overall survival (OS). We calculated LMR at baseline and a median of 21 days after the first cycle of ICI (on-treatment LMR), and defined low if < 2 and high if ≥ 2. OS was calculated from the initiation of ICI to date of death or censored at last follow-up. Results 1077 patients met the criteria for this study. Patients with low baseline LMR had a shorter median OS compared to patients with a high baseline LMR (8.5 vs 18.1 months, p < 0.01). In patients with a low baseline LMR, who on-treatment LMR increased to high had longer median OS compared to those whose on-treatment LMR remained low (16.8 vs 7.8 months, p < 0.001). Patients with a high baseline LMR and in whom on-treatment LMR remained high had longer median OS compared to patients with low on-treatment LMR (23.9 vs 9.2 months, p < 0.001). In multivariate analysis, high on-treatment LMR was most strongly associated with longer survival compared to low on-treatment LMR, regardless of baseline LMR. Conclusions Higher baseline and early changes in on-treatment LMR are associated with improved OS in cancer patients receiving ICI.

scholarly journals Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Po-Hsin Lee ◽  
Tsung-Ying Yang ◽  
Kun-Chieh Chen ◽  
Yen-Hsiang Huang ◽  
Jeng-Sen Tseng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pleural Effusion ◽  
Cancer Patients ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Lung Cancer Patients ◽  
Predicting Factor ◽  
Type 3

AbstractPleural effusion is a rare immune-related adverse event for lung cancer patients receiving immune checkpoint inhibitors (ICIs). We enrolled 281 lung cancer patients treated with ICIs and 17 were analyzed. We categorized the formation of pleural effusion into 3 patterns: type 1, rapid and massive; type 2, slow and indolent; and type 3, with disease progression. CD4/CD8 ratio of 1.93 was selected as the cutoff threshold to predict survival. Most patients of types 1 and 2 effusions possessed pleural effusion with CD4/CD8 ratios ≥ 1.93. The median OS time in type 1, 2, and 3 patients were not reached, 24.8, and 2.6 months, respectively. The median PFS time in type 1, 2, and 3 patients were 35.5, 30.2, and 1.4 months, respectively. The median OS for the group with pleural effusion CD4/CD8 ≥ 1.93 and < 1.93 were not reached and 2.6 months. The median PFS of those with pleural effusion CD4/CD8 ≥ 1.93 and < 1.93 were 18.4 and 1.2 months. In conclusion, patients with type 1 and 2 effusion patterns had better survival than those with type 3. Type 1 might be interpreted as pseudoprogression of malignant pleural effusion. CD4/CD8 ratio ≥ 1.93 in pleural effusion is a good predicting factor for PFS.

Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors

2021 ◽  
Author(s):  
Sudhakar Tummala ◽  
Xerxes Pundole ◽  
Jeffrey Aldrich ◽  
Maria E. Suarez‐Almazor
Keyword(s):  
Cancer Patients ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Inflammatory Myositis

Immune‐related adverse events in cancer patients being treated with immune checkpoint inhibitors

2021 ◽  
Author(s):  
Margaret M. Byrne ◽  
Mathew Lucas ◽  
Lori Pai ◽  
Janis Breeze ◽  
Susan K. Parsons
Keyword(s):  
Adverse Events ◽  
Cancer Patients ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors
Sign in / Sign up

Export Citation Format

Share Document